Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
2023-SR-002
Phase 2 small_molecule active
Quick answer
Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen for NK-T-Cell Lymphoma, Extranodal is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- NK-T-Cell Lymphoma, Extranodal
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active